Skip to main content
Clinical Trials/NCT02070900
NCT02070900UnknownNot Applicable

Does Provision of Point of Care CD4 Technology and Early Knowledge of CD4 Levels Affect Early Initiation and Retention on Anti-retroviral Treatment (ART) in HIV Positive Pregnant Women in the Context of Option B+ for PMTCT?

WHO, Department of Maternal, Newborn, Child and Adolescent Health32 sites in 1 country704 target enrollmentStarted: January 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
704
Locations
32
Primary Endpoint
Retention

Study Overview

Brief Summary

The study will be conducted at 32 health care facilities in three provinces in Zimbabwe and will compare the impact of the provision Point of Care CD4 technology and early knowledge of CD4 levels on retention at 12 months, with or without POC CD4 and a programmatic mentoring package. Option B+ will be implemented at all sites and 16 intervention sites will receive POC CD4 machines and visits from a team of clinical mentors.

The study also aims to assess rates of ART initiation and time to ART initiation of HIV positive pregnant women in settings implementing option B+ with or without POC CD4 and related counselling/support; rates of retention in care of HIV positive mothers at 6 months post ART initiation in settings implementing option B+ with or without POC CD4 and related counselling/support; rates of ART initiation and retention at 6 and 12 months post ART initiation according to different levels of CD4 count; cost of retaining HIV positive pregnant women until 6 and 12 months; acceptability and feasibility of POC CD4 as an adjunct to good clinical care of HIV positive pregnant women.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Pregnant at the time of booking
  • •HIV positive diagnosis
  • •Not on ART at the time of booking
  • •Present up to 38 weeks into gestation
  • •Presents more than 48 hours prior to delivery

Exclusion Criteria

  • •Already on ART at booking
  • •Presents more than 38 weeks into gestation or less than 48 hours prior to delivery

Arms & Interventions

Standard of Care

No Intervention

Sites implementing Option B+ for pregnant and lactating women according to the standard of care prescribed by the Ministry of health and Child Care national guidelines

POC Plus

Experimental

Sites implementing Option B+ according to the standard of care prescribed by the Ministry of Health and Child Care, as well as programmatic mentoring and POC CD4 machines

Intervention: POC CD4 (Device)

POC Plus

Experimental

Sites implementing Option B+ according to the standard of care prescribed by the Ministry of Health and Child Care, as well as programmatic mentoring and POC CD4 machines

Intervention: Programmatic Mentoring (Other)

Outcomes

Primary Outcomes

Retention

Time Frame: 12 months

Proportion of HIV positive pregnant women that are retained on ART, 12 months after initiation

Secondary Outcomes

  • Retention by CD4 count(6 months , 12 months)
  • Time-to-initiation(12 months)
  • Retention at 6 months(6 months)
  • Cost per pregnant woman retained on ART(6 months , 12 months)
  • Initiation within 1 month(1 month)

Investigators

Sponsor
WHO, Department of Maternal, Newborn, Child and Adolescent Health
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (32)

Loading locations...

Similar Trials